BCL‐XL exerts a protective role against anemia caused by radiation‐induced kidney damage

Discovery of A-1331852, a First-in-Class, Potent and Orally-Bioavailable BCL-XL Inhibitor

(2020) Le Wang et al.   ACS Medicinal Chemistry Letters

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

(2019) Sajid Khan et al.   NATURE MEDICINE

Embryogenesis and Adult Life in the Absence of Intrinsic Apoptosis Effectors BAX, BAK, and BOK

(2018) Francine F.S. Ke et al.   CELL

Targeting BCL-2 regulated apoptosis in cancer

(2018) Kirsteen J. Campbell et al.   Open Biology

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines

(2018) Delphine Merino et al.   CANCER CELL

A pathology atlas of the human cancer transcriptome

(2017) Mathias Uhlen et al.   SCIENCE

Reducing radiation-induced gastrointestinal toxicity — the role of the PHD/HIF axis

(2016) Monica M. Olcina et al.   JOURNAL OF CLINICAL INVESTIGATION

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

(2014) G. L. Kelly et al.   GENES & DEVELOPMENT

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure

(2013) R. L. Thomas et al.   GENES & DEVELOPMENT

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction

(2013) X. Wang et al.   GENES & DEVELOPMENT

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Inflammation and Immunity in Radiation Damage to the Gut Mucosa

(2013) Agnès François et al.   Biomed Research International

BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

(2012) Victoria Del Gaizo Moore et al.   CANCER LETTERS

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

The investigation and treatment of secondary anaemia

(2011) Sarah L. Davis et al.   BLOOD REVIEWS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Mitochondria and cell death: outer membrane permeabilization and beyond

(2010) Stephen W. G. Tait et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Chronic Kidney Disease After Hematopoietic Stem Cell Transplantation

(2010) Eric P. Cohen et al.   SEMINARS IN NEPHROLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION

Mcl-1 Is a Key Regulator of Apoptosis during CNS Development and after DNA Damage

(2008) N. Arbour et al.   JOURNAL OF NEUROSCIENCE

To Trigger Apoptosis, Bak Exposes Its BH3 Domain and Homodimerizes via BH3:Groove Interactions

(2008) Grant Dewson et al.   MOLECULAR CELL